Dobi Medical on track with breast cancer imager
This article was originally published in Clinica
Executive Summary
Dobi Medical International says it is on track with plans to submit a US marketing application for its angiogenesis-based breast cancer imaging system next summer. The Mahwah, New Jersey firm has begun a clinical trial which will be the subject of the fifth and final module of its premarket approval (PMA) application with the FDA for its flagship product, the ComfortScan system. Patient enrolment has now started at several leading medical centres, with additional sites expected to begin enrolling patients in early 2005.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.